KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) EBT (2016 - 2025)

Emergent BioSolutions' EBT history spans 15 years, with the latest figure at -$50.7 million for Q4 2025.

  • For Q4 2025, EBT fell 83.7% year-over-year to -$50.7 million; the TTM value through Dec 2025 reached $82.8 million, up 157.94%, while the annual FY2025 figure was $82.8 million, 157.94% up from the prior year.
  • EBT reached -$50.7 million in Q4 2025 per EBS's latest filing, down from $57.6 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $256.3 million in Q4 2021 to a low of -$269.8 million in Q2 2024.
  • Average EBT over 5 years is -$35.2 million, with a median of -$36.6 million recorded in 2021.
  • Peak YoY movement for EBT: crashed 4126.32% in 2023, then soared 666.12% in 2025.
  • A 5-year view of EBT shows it stood at $256.3 million in 2021, then tumbled by 123.96% to -$61.4 million in 2022, then rose by 11.24% to -$54.5 million in 2023, then soared by 49.36% to -$27.6 million in 2024, then tumbled by 83.7% to -$50.7 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's EBT are -$50.7 million (Q4 2025), $57.6 million (Q3 2025), and -$16.8 million (Q2 2025).